StockpollyBeta
Get App
Popularity #2,274
ASMB · NASDAQ · Biotechnology

Assembly Biosciences (ASMB)

Develops antiviral and liver-disease candidates through discovery and clinical development.

$25.40
vs last close−0.04 (−0.14%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue0769779101142813
Cost of revenue110001414151617000
Gross profit−11769−7−7−5−6−642813
420162145555232020
Research & development111112161414151617171515
495445555555
Selling & marketing000000000000
General & administrative495445555555
Other expenses−11000−14−14−15−16−17000
Operating income−15−13−11−12−11−12−10−11−1120−11−6
122111112222
Interest income122111112222
Other non-operating income0−2−2−1−1−1−1−1−2−2−2−2
Income before tax−14−11−9−11−10−10−9−10−922−9−4
Income tax expense000000000000
Net income from continuing operations−14−11−9−11−10−10−9−10−922−9−4
Net income−14−11−9−11−10−10−9−10−922−9−4
EPS, basic−$3.29−$2.00−$1.66−$1.98−$1.51−$1.72−$1.17−$1.33−$1.20$2.49−$0.54−$0.20
EPS, diluted−$3.29−$2.00−$1.66−$1.98−$1.51−$1.72−$1.17−$1.33−$1.20$2.49−$0.54−$0.20
Weighted average shares, basic455667888111719
Weighted average shares, diluted455667888111719
EBITDA−15−11−9−11−10−10−9−10−922−9−4
Depreciation & amortization000000000000
EBIT−15−11−9−11−10−10−9−10−922−9−4